Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles

J Pediatric Infect Dis Soc. 2021 Apr 3;10(3):363-366. doi: 10.1093/jpids/piaa089.

Abstract

We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01. A 4-year-old African American female with perinatally acquired human immunodeficiency virus infection was hospitalized for DRESS after starting a raltegravir-based antiretroviral regimen.

Keywords: antiretroviral therapy; drug-reaction with eosinophilia and systemic symptoms syndrome; human immunodeficiency virus; human leukocyte antigen-B alleles; raltegravir.

MeSH terms

  • Alleles
  • Child
  • Child, Preschool
  • Drug Hypersensitivity Syndrome* / genetics
  • Eosinophilia* / chemically induced
  • Female
  • HLA Antigens
  • HLA-B Antigens / genetics
  • Humans
  • Pharmaceutical Preparations*
  • Raltegravir Potassium / adverse effects

Substances

  • HLA Antigens
  • HLA-B Antigens
  • Pharmaceutical Preparations
  • Raltegravir Potassium